Alzheimer's disease (AD) is a progressive degenerative condition. In order to treat AD, the
use of a “drug repositioning” or “repurposing” approach with potential disease-modifying …

Background: Alzheimer's disease (AD) as an age-related, irreversible neurodegenerative
disease, characterized by cognitive dysfunction, has become progressively serious with a …

Rationale Acetylcholinesterase inhibitors are widely used for the treatment of patients with
Alzheimer's disease (AD). However, the relationship between the capacity of such drugs to …

Alzheimer's disease (AD) is a neurodegenerative disease characterized by sequential
progression of pathological events, such as aggregation of amyloid-β proteins, followed by …

Background Sitagliptin is an anti-diabetic drug and its effects on Alzheimer's disease (AD)
remain controversial. This study aimed to investigate the protective effect of sitagliptin on the …

Alzheimer's disease (AD) is a progressive neurodegenerative disease. In this study, to
investigate the effect of microglial elimination on AD progression, we administered …

SCM-198 is an alkaloid found only in Herba leonuri and it has been reported to possess
considerable neuroprotective effects in animal models of ischemic stroke, Parkinson's …

Alzheimer's disease is characterized by a progressive decline in cognitive function and
involves β-amyloid (Aβ) in its pathogenesis. To characterize cognitive deficits associated …

Alzheimer's disease (AD) is an age-related neurodegenerative disease, which characterized
by deposition of amyloid-β (Aβ) plaques, neurofibrillary tangles, neuronal loss, and …

Fluoxetine (FLX) is one of the selective serotonin reuptake inhibitors (SSRIs)
antidepressants, which could be used to relieve depression and anxiety among AD patients …